Clinical Trial Update: Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP) [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial assessing the safety and efficacy of Sym001 for Immune Thrombocytopenic Purpura has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• Sym001

Snippet

Sponsor: Symphogen A/S | Conditions: Immune Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED